Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.67 |
| ▸ | CTSD | P07339 | 1/20 | 0.66 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512850 | 0.91 | BACE1 (0.67) | BACE1CTSDBACE2 | |
| SCHEMBL29598002 | 0.90 | BACE1 (0.68) | BACE1CTSDBACE2 | |
| SCHEMBL29798264 | 0.90 | BACE1 (0.64) | BACE1CTSDBACE2 | |
| SCHEMBL29522218 | 0.89 | BACE1 (0.62) | BACE1CTSDBACE2 | |
| SCHEMBL29443821 | 0.89 | BACE1 (0.65) | BACE1CTSDBACE2 | |
| SCHEMBL29798016 | 0.88 | BACE1 (0.61) | BACE1CTSDBACE2 | |
| SCHEMBL29679577 | 0.87 | BACE1 (0.63) | BACE1CTSDBACE2 | |
| SCHEMBL31733014 | 0.87 | BACE1 (0.67) | BACE1CTSDBACE2 | |
| SCHEMBL31575679 | 0.87 | BACE1 (0.67) | BACE1CTSDBACE2 | |
| SCHEMBL30369652 | 0.87 | BACE1 (0.63) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062756-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | H LEE MOFFITT CANCER CT & RES (US) | 2026-03-05 | — | — | US | claimed |
| US-20240218454-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-07-04 | — | — | US | claimed |
| WO-2022226381-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| US-20260126454-A1 | MASS SPECTROMETRY ANALYSIS OF MARKERS FOR ALZHEIMER'S DISEASE | EMORY UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260094799-A1 | METHOD AND ASSEMBLY FOR HANDLING GAS-PHASE IONS | BRUKER SWITZERLAND AG (CH) | 2026-04-02 | — | — | US | disclosed |
| EP-4718068-A1 | METHOD AND ASSEMBLY FOR HANDLING GAS-PHASE IONS | Bruker Switzerland AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260062756-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | H LEE MOFFITT CANCER CT & RES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250389733-A1 | Method for determining risk factors for neurodegenerative diseases in blood | WANG JIJING (SE) | 2025-12-25 | — | — | US | disclosed |
| WO-2025226207-A1 | METHOD FOR IDENTIFYING AND CHARACTERIZING AN ANTI-MODIFIED PROTEIN ANTIBODY ASSOCIATED WITH A PATHOLOGICAL CONDITION RELATED TO OR CAUSED BY INFLAMMATION OR A DYSREGULATED IMMUNE SYSTEM | THERIM RESEARCH AB (SE) | 2025-10-30 | — | — | WO | disclosed |
| EP-4549945-A1 | ASSESSMENT-SUPPORTING INFORMATION GENERATING METHOD, ASSESSMENT-SUPPORTING INFORMATION GENERATING SYSTEM, AND INFORMATION PROCESSING DEVICE | MCBI INC. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12247977-B2 | Nasopharyngeal protein biomarkers of acute respiratory virus infection and methods of using same | DUKE UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230101980-A1 | METHOD, SYSTEM AND APPARATUS FOR SUBSTANCE IDENTIFICATION | Trillitye PAULLIN (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023038560-A1 | METHOD FOR DETERMINING RISK FACTORS FOR NEURODEGENERATIVE DISEASES IN BLOOD | ZUBAREV ROMAN (SE) | 2023-03-16 | — | — | WO | disclosed |
| US-11573219-B2 | LC/MS/MS analysis for meat speciation in raw and processed meat product | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2023-02-07 | — | — | US | disclosed |
| WO-2022226381-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220275417-A1 | METHOD FOR MANUFACTURING MONOCLONAL ANTIBODY USING YEAST, AND SCREENING METHOD | BARCODEBODY INC. (JP) | 2022-09-01 | — | — | US | disclosed |
| US-20220265755-A1 | ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION | BCELL SOLUTIONS, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-3510392-B1 | LC/MS/MS ANALYSIS FOR MEAT SPECIATION IN RAW AND PROCESSED MEAT PRODUCT | DH TECHNOLOGIES DEV PTE LTD (SG) | 2022-02-16 | — | — | EP | disclosed |
| US-20220034901-A1 | QUANTITATION OF GLA PROTEINS BY MASS SPECTROMETRIC ANALYSIS | UNIVERSITY OF WASHINGTON (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220026440-A1 | CONTAINER AND METHOD FOR STORING, PRETREATING, AND ANALYZING BIOMATERIAL | NISSAN CHEMICAL CORPORATION (JP) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260094799-A1 | METHOD AND ASSEMBLY FOR HANDLING GAS-PHASE IONS | RFC3, RFC2, RAD1 | BACE1 3750/4885CTSD 2931/4885BACE2 3571/4885 |
| US-20250389733-A1 | Method for determining risk factors for neurodegenerative diseases in blood | ASS1, PCMT1, NEFM | BACE1 1632/4885CTSD 2187/4885BACE2 1750/4885 |
| US-20260126454-A1 | MASS SPECTROMETRY ANALYSIS OF MARKERS FOR ALZHEIMER'S DISEASE | APP, BACE1, BACE2 | BACE1 2/4885CTSD 531/4885BACE2 3/4885 |
| US-20260062756-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | CDK12, CHEK1, AURKB | BACE1 2914/4885CTSD 3042/4885BACE2 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.